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Synchronous malignancies: A tale of two different tumors
Editor, Synchronous tumors refer to occurrence of a second malignancy in a patient with a known primary. While synchronous lesions occur within 6 months of diagnosis of a previous neoplasm, metachronus tumors occur >6 months apart. [1] While nationwide frequency of thyroid cancer in Indian population has been reported to be only 0.1%-0.2% of all cancers, [2] breast cancer is now the most common cancer in Indian females in most cities and is on a rising trend. [3] A 55-year-old postmenopausal female presented with 3 × 3 cm right breast lump for 10 months. Radiological findings were suggestive of BIRADS IV lesion [ Figure 1a ]. General patient examination revealed another diffuse midline neck bulge measuring approximately 3 × 3 cm, moving with deglutition. The patient had not suspected a neck swelling otherwise. A contrast enhanced computed tomography of neck, chest, and abdomen was done, which revealed discrete lesions in breast and thyroid [ Figure 1b Figure 3a -g] showed highly cellular smears with follicular epithelial cells arranged in large papillary fragments and sheets. Considerable nuclear overlapping and overcrowding with characteristic intranuclear grooves and inclusions were noted. Background showed thick and thin colloid with scattered hurthle cells. Thus, confirming diagnosis of papillary carcinoma thyroid (Bethesda Category 6). Pre-op molecular testing for BRAF (V600E) was not done as the cytomorphology was diagnostic. Our patient underwent trucut biopsy from the breast lesion and a total thyroidectomy. Features were suggestive of Infiltrating duct carcinoma, no special type [ Figure 2g and h]. Molecular subtype was basal like; triple negative for ER, PR, and Her-2neu [ Figure 2i ]. The patient also underwent total thyroidectomy which on microscopy was diagnostic of well differentiated, papillary carcinoma thyroid (pT2) with microinvasion in the right lobe, and colloid goiter in the isthmus [ Figure 3h and i]. On follow-up, the patient has currently undergone four cycles of chemotherapy (CAF regimen) and is planned for radical mastectomy after six cycles.
(b) Pleomorphic cells clusters with intervening pink stromal material (Giemsa; 400×). (c) Tumor cells show prominent nucleoli owed (Giemsa; 400×). Cell block smears revealed cellular polygonal cell clusters. (d) (H and E; 40×). (e and f) (H and E; 400×). Trucut breast biopsy: (g) pleomorphic nests of epithelial cells showing high-grade nuclear atypia (H and E; 100×). (h) Cell clusters had moderate eosinophilic to foamy cytoplasm (H and E; 400×). (i) IHC for ER, PR, and Her2neu was negative
The association between thyroid disorders and breast neoplasms has been a matter of debates for decades. Recent papers have highlighted the complex interplay by demonstrating that on one hand, L-thyroxine, T 4 , has a proliferative effect in vitro on breast cancer cells, and even in the absence of estrogen, thyroid hormone can promote nuclear estrogen receptor-α (ERα)-dependent proliferation of breast cancer cells bearing this receptor. On the other hand, clinical evidence exists establishing beneficial effects of hypothyroidism on the course of breast cancer. [4] Nio et al. in their large-scale observational study found that patients with thyroid disorders (thyroid cancer, adenoma, or adenomatous goiter) had an increase incidence of developing breast cancer; however, vice versa was not true. [5] Several key factors have been attributed to this mosaic entanglement between thyroid and breast. A beneficial role of thyroid peroxidase antibodies (TPOAbs) in patients with breast cancer has been demonstrated in few studies with a potential for targeted therapy. [6] Interestingly, Nielsen et al. attributed shared genetic susceptibility as observed by germline mutation in the tumor suppressor gene, PTEN, succinate dehydrogenase (SDHx), and KLLN to be the link between these two organs. [7] An underrecognized role of multiorgan cancer susceptibility gene, CHEK2, is also suspected in multiorgan carcinogenesis and responsible for defective DNA damage repair. [8] There exists a causal relationship between thyroid malignancy and carcinoma breast. Several pathogenic mechanisms and theories have been suggested; however, none is conclusive. Through the present case, we highlight the coexistence of these two lesions along with importance of multisystem examination in a patient diagnosed with either thyroid or breast malignancy.
